Effects of combination lipid therapy in type 2 diabetes mellitus (scientific article)

cites work (P2860)

Q41501265	"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study
Q38009358	'Omics'-driven discoveries in prevention and treatment of type 2 diabetes
Q28301815	2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Q49396285	2016 Chinese guidelines for the management of dyslipidemia in adults.
Q50065204	2017 EACTS Guidelines on perioperative medication in adult cardiac surgery.
Q98613612	2018 Guidelines for the Management of Dyslipidemia in Korea
Q91611086	2018 Guidelines for the management of dyslipidemia
Q42950463	4th Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 12-14, 2011, Budapest, Hungary
Q51743168	A Clinical Guide to Combination Lipid-Lowering Therapy.
Q50320306	A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.
Q37672465	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids
Q30048180	A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
Q38106667	A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative.
Q37183153	A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia
Q37179792	A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies
Q88564337	A low-fat spread with added plant sterols and fish omega-3 fatty acids lowers serum triglyceride and LDL-cholesterol concentrations in individuals with modest hypercholesterolaemia and hypertriglyceridaemia
Q38113494	A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs
Q38575410	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Q36011053	A review of time courses and predictors of lipid changes with fenofibric acid-statin combination
Q36988873	A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease
Q57046350	ABCA1 Overexpression in Endothelial Cells In Vitro Enhances ApoAI-Mediated Cholesterol Efflux and Decreases Inflammation
Q84791986	ACCORD(ing) to a Trialist
Q40104818	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy
Q37851958	AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types
Q43043483	Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.
Q34757030	Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus
Q34291764	Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study
Q48889942	Activation of PPAR-α in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure.
Q38236677	Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia
Q36976354	Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study).
Q36181341	Adiponectin and all-cause mortality in elderly people with type 2 diabetes
Q30404697	Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management.
Q47687003	Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes
Q37520014	Advanced glycation end products (AGE) and diabetes: cause, effect, or both?
Q50123830	Advances in lipid-lowering therapy through gene-silencing technologies.
Q35750181	Advancing cardiovascular research.
Q34549774	Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials
Q37280867	Albuminuria and cognitive decline in people with diabetes and normal renal function
Q35682234	Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View
Q38206839	Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody
Q50047295	Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
Q45420980	All at sea: new lipid-lowering drug trials continue to disappoint
Q34081331	American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary
Q42944964	American Diabetes Association Postgraduate Meetings--2011.
Q36328050	An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
Q35569823	An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature
Q35957903	An Uninformative Truth: The Logic of Amarin's Off-Label Promotion
Q38032616	An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels
Q35050146	An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes
Q29999973	Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
Q37677869	Analysis of risk factors and their interactions in type 2 diabetes mellitus: A cross-sectional survey in Guilin, China
Q38296685	Antilipidemic Drug Therapy Today and in the Future
Q33725659	ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity
Q35845617	ApoE isoforms, treatment of diabetes and the risk of coronary heart disease
Q33773561	Application of random forests methods to diabetic retinopathy classification analyses
Q26996187	Applications of mass spectrometry for cellular lipid analysis
Q28074451	Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future
Q37308578	Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes
Q36975446	Assessing appropriateness of lipid management among patients with diabetes mellitus: moving from target to treatment
Q90145015	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
Q49724237	Association between Knowledge-Attitude-Practices and Control of Blood Glucose, Blood Pressure, and Blood Lipids in Patients with Type 2 Diabetes in Shanghai, China: A Cross-Sectional Study.
Q40998829	Association between atherogenic dyslipidemia and recurrent stroke risk in patients with different subtypes of ischemic stroke
Q37281210	Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence
Q38837647	Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number: The Multi-Ethnic Study of Atherosclerosis.
Q38383033	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
Q38758014	Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients
Q34649579	Association of cholesteryl ester transfer protein (CETP) gene polymorphism, high density lipoprotein cholesterol and risk of coronary artery disease: a meta-analysis using a Mendelian randomization approach
Q35032753	Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies
Q37569809	Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy
Q33776194	Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials
Q37119482	Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.
Q50044256	Atherogenic index of plasma is an effective index for estimating abdominal obesity.
Q37832648	Atherosclerosis in 2010: new therapeutic insights
Q37786650	Atherosclerosis regression and high-density lipoproteins
Q33724722	Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol
Q47801721	Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong
Q36820247	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update
Q36796520	Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise
Q53695752	Awareness of diabetic retinopathy among people with diabetes in Jeddah, Saudi Arabia.
Q35809770	Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies
Q59795787	Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study
Q26853571	Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes
Q35688214	Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Q38100747	Beyond statins: lipid management to reduce cardiovascular risk
Q38207925	Beyond statins: new lipid lowering strategies to reduce cardiovascular risk
Q36489752	Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
Q57819059	Bilirubin, a Cardiometabolic Signaling Molecule
Q38164674	Biologics for the treatment of dyslipidemias: a look beyond conventional therapy
Q37661945	Biomarkers, Risk Factors, and Risk: Clarifying the Controversy About Surrogate End Points and Clinical Outcomes
Q36217449	Biophysiologic outcomes of the Enhancing Adherence in Type 2 Diabetes (ENHANCE) trial
Q36281537	Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies
Q34005250	Blood pressure control in type 2 diabetes mellitus
Q34467152	Blood pressure lowering in patients with diabetes--one level might not fit all.
Q33908782	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB
Q27687570	Calcium and phosphate impact cardiovascular risk
Q46962453	Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Q47557757	Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment
Q36117824	Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases
Q38176275	Cardiometabolic impact of non-statin lipid lowering therapies
Q37161933	Cardiometabolic interventions - focus on transcriptional regulators
Q57931390	Cardiovascular Disease and Diabetes: Two Sides of the Same Coin!
Q52571293	Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus.
Q57115068	Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia
Q37023878	Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials
Q42398936	Cardiovascular disease and glycemic treatment
Q39420208	Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Q34552320	Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study
Q36419283	Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities
Q37803337	Cardiovascular drug therapy in the elderly: benefits and challenges
Q34241802	Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data
Q38902200	Cardiovascular inflammation is reduced with methotrexate in diabetes
Q37811044	Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies.
Q26825634	Cardiovascular risk
Q40100018	Cardiovascular risk and dyslipidemia among persons living with HIV: a review
Q37089769	Cerebrovascular complications of diabetes: focus on stroke
Q102059024	Cessation of Bezafibrate in patients with chronic kidney disease improves renal function
Q51301866	Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?
Q37173568	Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy
Q86553722	Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD
Q86553726	Chapter 5: Referral to specialists and models of care
Q87393564	Chapter 5: Triglyceride-lowering treatment in adults
Q37571916	Characteristics associated with informed consent for genetic studies in the ACCORD trial
Q38832774	Cholesteryl ester transfer protein inhibitors: challenges and perspectives
Q48799668	Choosing targets for glycaemia, blood pressure and low-density lipoprotein cholesterol in elderly individuals with diabetes mellitus.
Q48211230	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes
Q60727666	Circulating HDL levels control hypothalamic astrogliosis via apoA-I
Q57101827	Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis
Q64075657	Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
Q89585086	Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy
Q37011769	Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations
Q26752950	Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
Q35070830	Clinician's guide to the updated ABCs of cardiovascular disease prevention
Q28728567	Clustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapy
Q42931503	Coenzyme Q(10) and statin myalgia: what is the evidence?
Q35581159	Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial
Q88868163	Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events
Q37842472	Combination lipid therapy in type 2 diabetes mellitus
Q35101789	Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial
Q42853404	Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies
Q99732140	Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet
Q37855939	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus
Q37982202	Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review
Q57426309	Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial
Q28659915	Common variants associated with plasma triglycerides and risk for coronary artery disease
Q33808664	Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients
Q46103710	Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias
Q64256576	Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis
Q55398460	Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis.
Q36268257	Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials
Q38232357	Congenital lipodystrophies and dyslipidemias
Q34980772	Consensus statement on management of dyslipidemia in Indian subjects
Q34351961	Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues
Q38186099	Critical review of non-statin treatments for dyslipoproteinemia.
Q38982216	Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes
Q38649661	Current Controversies With Recent Cholesterol Treatment Guidelines.
Q38124404	Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia
Q38546242	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
Q38338437	Current drug treatment of hyperlipidemia in older adults.
Q37702199	Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.
Q33646780	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
Q37196514	Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
Q51317678	Dan-gua fang improves glycolipid metabolic disorders by promoting hepatic adenosine 5'-monophosphate activated protein kinase expression in diabetic Goto-Kakizaki rats.
Q37775820	Darapladib: an emerging therapy for atherosclerosis
Q90748230	Defective Mitochondrial Fatty Acid Oxidation and Lipotoxicity in Kidney Diseases
Q38141575	Demystifying the management of hypertriglyceridaemia.
Q34014812	Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis
Q93160429	Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease -
Q33730396	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
Q37719009	Determinants of Treatment Modification in Hypercholesterolemic Patients
Q38627117	Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials
Q34218665	Development of a new diabetes risk prediction tool for incident coronary heart disease events: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study
Q26750905	Diabetes Dyslipidemia
Q33647298	Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society.
Q36783914	Diabetes and cardiovascular disease: when it comes to lipids, statins are all you need
Q38109814	Diabetes and its comorbidities--where East meets West
Q36331397	Diabetes control among Hispanics in the action to control cardiovascular risk in diabetes trial
Q30528669	Diabetes in older adults
Q34308751	Diabetes in older adults: a consensus report
Q38977597	Diabetes management in older people: a focus on cardiovascular risk reduction
Q42818447	Diabetes mellitus and cardiovascular risk. Is integrated therapy of type 2 diabetes and cardiovascular risk factors necessary?
Q37984922	Diabetes, hyperglycaemia, and acute ischaemic stroke
Q44864407	Diabetes. Cognitive decline and T2DM--a disconnect in the evidence?
Q83474625	Diabetes: Should we use fibrates in patients with diabetes and mild CKD?
Q57475590	Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies
Q37737551	Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.
Q28067479	Diagnosis and treatment of high density lipoprotein deficiency
Q36864306	Diagnostic Utility of Serum Glycated Albumin for Diabetes Mellitus and Its Correlation With Hyperlipidemia
Q36964616	Differential Benefit of Statin in Secondary Prevention of Acute Myocardial Infarction according to the Level of Triglyceride and High Density Lipoprotein Cholesterol.
Q42380215	Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action
Q39214885	Distinct but complementary contributions of PPAR isotypes to energy homeostasis.
Q33776187	Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
Q38067634	Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?
Q37763196	Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?
Q46380487	Doubling up: maximising statin therapy as opposed to adding other drugs for cardiovascular disease prevention
Q39102158	Drug Therapy for Stable Angina Pectoris
Q38654327	Drug therapies to delay the progression of chronic kidney disease
Q37771014	Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs
Q34036950	Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects
Q37053287	Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?
Q38773023	Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy
Q38195433	Dysglycaemia, vasculopenia, and the chronic consequences of diabetes
Q39424127	Dyslipidaemia and its treatment in patients with type 2 diabetes - a joint analysis of the German DIVE and DPV registries.
Q50180407	Dyslipidaemia in the elderly: to treat or not to treat?
Q37772510	Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies
Q86518885	Dyslipidaemia: Failure to THRIVE: the end for niacin?
Q54394383	Dyslipidaemia: Small triumph for fenofibrate therapy in dyslipidaemia.
Q84914747	Dyslipidaemia: integration between primary and secondary care
Q38777322	Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease
Q38508952	Dyslipidemia and cardiovascular disease in women
Q26851294	Dyslipidemia and its therapeutic challenges in renal transplantation
Q36994072	Dyslipidemia in obesity: mechanisms and potential targets
Q38088216	Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management
Q37582481	Dyslipidemia in women: etiology and management
Q26765157	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies
Q33776181	Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.
Q38049066	Dyslipidemia: management using optimal lipid-lowering therapy
Q33776176	Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials
Q22241786	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary
Q38325814	Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
Q36868150	Early-adulthood cardiovascular disease risk factor profiles among individuals with and without diabetes in the Framingham Heart Study
Q41001502	Editorial on hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol goals in diabetics
Q41223740	Effect of Fenofibrate Medication on Renal Function
Q90481227	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial
Q40421283	Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial.
Q36277659	Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial
Q38377128	Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium
Q90481174	Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinica
Q48173359	Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
Q91934331	Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial
Q46945180	Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.
Q89608566	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
Q51385582	Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose.
Q36560348	Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial
Q33831184	Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects
Q57031067	Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction
Q37484551	Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome
Q38452702	Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial
Q38856838	Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review
Q86927304	Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study
Q45327091	Effect of selected clinical trial publication on adjunctive nonstatin medication prescribing in the Veterans Health Administration system
Q30364133	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.
Q38434603	Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Q28244205	Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Q58127107	Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT
Q64947749	Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis.
Q51565743	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Q34262967	Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
Q38293501	Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function
Q57274310	Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
Q45535226	Effects of fibrates on cardiovascular outcomes
Q61873322	Effects of fibrates on cardiovascular outcomes – Authors' reply
Q33576435	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
Q34008161	Effects of intensive blood-pressure control in type 2 diabetes mellitus
Q30840447	Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial
Q35129072	Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.
Q33620031	Effects of medical therapies on retinopathy progression in type 2 diabetes
Q51371652	Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
Q33855092	Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease
Q57591322	Effects of non-statin antilipemic drugs on vascular endothelial function in patients with type 2 diabetes with hypercholesterolemia
Q35189566	Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study
Q34206025	Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism
Q52599940	Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Q51744121	Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease.
Q59652471	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II t
Q64114401	Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study
Q37436379	Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-blind, randomized, placebo-controlled study
Q93377781	Efficacy of negative pressure wound therapy using vacuum-assisted closure combined with photon therapy for management of diabetic foot ulcers
Q37074239	Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents
Q55107177	Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease.
Q90655312	Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Q51334679	Emerging approaches for the treatment of hypertriglyceridemia.
Q38263909	Emerging drugs for hyperlipidaemia: an update
Q38075029	Emerging drugs for managing kidney disease in patients with diabetes.
Q38613935	Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids
Q38217102	Emerging therapeutic approaches to treat dyslipidemia
Q34335153	Epidemiology, comparative effectiveness research, and the National Institutes of Health: forces for health
Q37288105	Established and emerging approaches for the management of dyslipidaemia
Q64285261	Evaluating All Potential Oral Complications of Diabetes Mellitus
Q24608464	Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline
Q37812387	Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy
Q83749876	Evidence-based medicine and the selection of lipid-lowering therapy in type 2 diabetes
Q84007797	Evidence-based medicine should be practiced for primary prevention and secondary prevention of cardiovascular disease
Q47769899	Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future.
Q34880292	Evolving targets for lipid-modifying therapy
Q38074336	Evolving therapeutic options for type 2 diabetes mellitus: an overview
Q38058381	Examining the safety of PPAR agonists - current trends and future prospects
Q36087108	Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation
Q89850024	Factors Associated with Poor Glycemic and Lipid Levels in Ambulatory Diabetes Mellitus Type 2 Patients in Asmara, Eritrea: A Cross-Sectional Study
Q36703114	Facts and principles learned at the 39th Annual Williamsburg Conference on Heart Disease
Q44206732	Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Q46488015	Façons d’identifier et de prendre en charge la dyslipidémie athérogène: Une conséquence métabolique de l’obésité et du diabète
Q35103583	Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans.
Q40777122	Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.
Q37612824	Fenofibrate and metabolic syndrome
Q38088377	Fenofibrate and the kidney: an overview.
Q37681585	Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study
Q37898699	Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
Q101217453	Fenofibrate prevents iron induced activation of canonical Wnt/β-catenin and oxidative stress signaling in the retina
Q42281309	Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases
Q30419020	Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
Q38118853	Fenofibrate-associated nephrotoxicity: a review of current evidence
Q37653029	Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
Q33933474	Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus
Q95794110	Fenofibrate: a review of its use in dyslipidaemia
Q37992119	Fenofibric acid for hyperlipidemia
Q37771902	Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found
Q94454408	Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Q42218338	Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2.
Q38260501	Fibrates and niacin: is there a place for them in clinical practice?
Q21246041	Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
Q84372846	Fibrates consistently lower risk of cardiovascular events across high-risk groups
Q24203618	Fibrates for primary prevention of cardiovascular disease events
Q30241199	Fibrates for primary prevention of cardiovascular disease events.
Q24186376	Fibrates for secondary prevention of cardiovascular disease and stroke
Q43050781	Fibrates in CVD: a step towards personalised medicine
Q49571281	Fibrates in the management of atherogenic dyslipidemia.
Q84960836	Fibrates reduce the risk of major cardiovascular and coronary events compared with placebo, but do not affect risk of cardiovascular or all-cause mortality
Q34796255	Fish oil and the pan-PPAR agonist tetradecylthioacetic acid affect the amino acid and carnitine metabolism in rats
Q86118649	Fish oils, coronary heart disease, and the environment
Q37448634	Four Statin Benefit Groups Defined by The 2013 ACC/AHA New Cholesterol Guideline are Characterized by Increased Plasma Level of Electronegative Low-Density Lipoprotein.
Q37030996	Frail HDLs and stiff arteries in type 2 diabetes in juveniles
Q38200673	Gamma-glutamyltransferase predicts increased risk of mortality: a systematic review and meta-analysis of prospective observational studies
Q57148091	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial
Q44874088	Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.
Q36573908	Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction
Q36195926	Glucose control and cardiovascular outcomes: reorienting approach
Q38736800	Glucose targets for preventing diabetic kidney disease and its progression
Q61455627	Glycemic and blood-pressure control—lower is not better
Q38720697	Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease.
Q37251490	Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association
Q93109141	HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk
Q34614842	HDL and cognition in neurodegenerative disorders.
Q30251918	HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation
Q38739884	HDL cholesterol: reappraisal of its clinical relevance
Q38195221	HDL hypothesis: where do we stand now?
Q36918309	HDL, Atherosclerosis, and Emerging Therapies
Q46866176	HDL--is it too big to fail?
Q38087383	HDL-C: clinical equipoise and vascular endothelial function
Q38214018	HDL-targeted therapies: progress, failures and future
Q26782972	HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
Q38217089	HDL: to treat or not to treat?
Q36691768	Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature
Q34758108	Health outcomes in diabetics measured with Minnesota Community Measurement quality metrics.
Q36425790	High Human Cytomegalovirus IgG Level is Associated with Increased Incidence of Diabetic Atherosclerosis in Type 2 Diabetes Mellitus Patients
Q58130023	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk
Q37043222	High density lipoprotein and cardiovascular diseases.
Q26750603	High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties
Q37264429	High density lipoprotein: a therapeutic target in type 2 diabetes
Q83426043	High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia
Q93026142	High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus
Q38965138	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.
Q36139932	High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).
Q33876182	Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more
Q35738372	How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?
Q38824420	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.
Q36609968	Hyperlipidemia as a risk factor for cardiovascular disease
Q37803231	Hypertension 2010: what was new for the cardiologist?
Q37861888	Hypertension and lipid management in prediabetic states
Q39181612	Hypertriglyceridaemia and risk of coronary artery disease
Q92793323	Hypertriglyceridaemia predicts subsequent long-term risk of cardiovascular events in Chinese adults: 23-year follow-up of the Daqing Diabetes Study
Q60533968	Hypertriglyceridemia
Q49798045	Hypertriglyceridemia - Common Causes, Prevention and treatment Strategies
Q35571714	Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
Q26750954	Hypertriglyceridemia and Cardiovascular Diseases: Revisited
Q47180199	Hypertriglyceridemia and atherosclerosis
Q88697605	Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
Q55176268	Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care.
Q34687470	Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Q30244825	Hypertriglyceridemia: the importance of identifying patients at risk
Q38108834	Icosapent ethyl for the treatment of hypertriglyceridemia
Q33580249	Impact of admission triglyceride for early outcome in diabetic patients with stable coronary artery disease
Q49221091	Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention.
Q40740507	Impact of lipid metabolism parameters on the development and progression of coronary artery disease : An update
Q64979817	Impediments to clinical application of exercise interventions in the treatment of cardiometabolic disease.
Q33706621	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Q38393758	Improving the odds: ezetimibe and cardiovascular disease
Q37577126	In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion
Q35233119	Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study
Q37236166	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response
Q47844045	Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Q36721159	Increased Rosuvastatin Dose versus Concomitant Fenofibrate and Rosuvastatin Therapy to Achieve Lipid Goal in Patients with Diabetes or Atherosclerosis with Metabolic Syndrome
Q38786058	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Q93049588	Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia
Q35936964	Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia.
Q38001736	Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia
Q57688763	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Q37636062	Insulin-regulated protein palmitoylation impacts endothelial cell function.
Q38068591	Intensive blood pressure control in obese diabetic patients: clinical relevance of stroke prevention in the ACCORD trial
Q34083400	Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
Q26777184	Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia
Q36302771	Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia
Q36783920	Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): outcome studies versus clinical experience in the treatment of diabetes
Q37964753	Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?
Q30372692	Is fenofibrate a reasonable treatment for diabetic microvascular disease?
Q36664118	Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes?
Q30397875	Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention
Q36011273	Is the ratio of apoB/apoA-1 the best predictor for the severity of coronary artery lesions in Chinese diabetics with stable angina pectoris? An assessment based on Gensini scores
Q35871962	Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?
Q49245728	J Curve in Hypertension.
Q58362346	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
Q55069710	Japanese Clinical Practice Guideline for Diabetes 2016.
Q38240747	LDL cholesterol: controversies and future therapeutic directions
Q64355400	LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study
Q38511045	LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?
Q46942263	LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes.
Q35747811	LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
Q36721783	Lack of Association between High-Density Lipoprotein Cholesterol and Angiographic Coronary Lesion Severity in Chinese Patients with Low Background Low-Density Lipoprotein Cholesterol
Q38110701	Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.
Q90079595	Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study
Q91760069	Leveraging Genetics to Improve Cardiovascular Health in Diabetes: The 2018 Edwin Bierman Award Lecture
Q92150307	Life Style Intervention Improves Retinopathy Status-The Finnish Diabetes Prevention Study
Q36947413	Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study
Q33559274	Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
Q33567290	Lipid Lowering Therapy to Modify Plaque Microstructures.
Q27024982	Lipid abnormalities in kidney disease and management strategies
Q34419027	Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study
Q37853015	Lipid control in patients with diabetes mellitus
Q37902579	Lipid lowering therapy in type 2 diabetes
Q34530349	Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention
Q34131027	Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides
Q38589286	Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future
Q38118034	Lipid-lowering agents
Q27024352	Lipid-lowering agents in the management of nonalcoholic fatty liver disease
Q37859778	Lipid-lowering effects of ezetimibe and simvastatin in combination
Q35232239	Lipid-lowering therapy in older persons
Q26827432	Lipid-lowering therapy: who can benefit?
Q47769390	Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions
Q34734402	Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice.
Q92990898	Lipoprotein Lipase Inhibitor, Nordihydroguaiaretic Acid, Aggravates Metabolic Phenotypes and Alters HDL Particle Size in the Western Diet-Fed db/db Mice
Q58593985	Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes
Q33851861	Long-term effects of intensive glucose lowering on cardiovascular outcomes
Q36472753	Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study
Q34757003	Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides
Q88216068	Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM)
Q37170469	Longitudinal Patterns of Blood Pressure, Incident Cardiovascular Events, and All-Cause Mortality in Normotensive Diabetic People
Q34154005	Longitudinal changes in dietary fat intake and associated changes in cardiovascular risk factors in adults with type 2 diabetes: the ACCORD trial.
Q36892763	Loss of PPARα perpetuates sex differences in stroke reflected by peripheral immune mechanisms
Q30408720	Loss-of-function mutations in APOC3, triglycerides, and coronary disease
Q34731504	Low HDL-C level is associated with the development of intracranial artery stenosis: analysis from the Chinese IntraCranial AtheroSclerosis (CICAS) study
Q35810903	Low Plasma Hdl Cholesterol and Elevated C Reactive Protein further Increase Cardiovascular Disease Risk in Latinos with Type 2 Diabetes
Q35650429	Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
Q48327312	Low triglyceride as a marker for increased risk of cardiovascular diseases in patients with long-term type 2 diabetes: A cross-sectional survey in China.
Q57796293	Lower extremity arterial disease in patients with diabetes: a contemporary narrative review
Q33890208	Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
Q35230819	Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
Q50099270	Magnolol-mediated regulation of plasma triglyceride through affecting lipoprotein lipase activity in apolipoprotein A5 knock-in mice.
Q55464963	Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment.
Q30249076	Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?
Q37689636	Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review
Q64262692	Management of diabetic dyslipidemia: An update
Q38039980	Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.
Q34068746	Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Q33935729	Management of hypertriglyceridemia in the diabetic patient
Q34509936	Management of low levels of high-density lipoprotein-cholesterol
Q38106502	Management of the patient with diabetes and coronary artery disease: a contemporary review
Q37102861	Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes
Q50179675	Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.
Q37965730	Mapping body fat distribution: a key step towards the identification of the vulnerable patient?
Q33643266	Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes
Q38079914	Medical management and strategies to prevent coronary artery disease in patients with type 2 diabetes mellitus.
Q33855386	Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies
Q38083007	Medical management of stable coronary atherosclerosis.
Q37875489	Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke
Q48231572	Mendelian randomisation study of the associations of vitamin B12 and folate genetic risk scores with blood pressure and fasting serum lipid levels in three Danish population-based studies.
Q84187504	Mendelian randomisation, triglycerides, and CHD
Q37901053	Metabolic syndrome: nature, therapeutic solutions and options
Q64083675	Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management
Q26829098	Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
Q34594935	Molecular Implications of the PPARs in the Diabetic Eye.
Q34099937	Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes.
Q37254899	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes
Q38843479	Monoclonal Antibodies for Lipid Management
Q52673953	Myeloperoxidase mediated HDL oxidation and HDL proteome changes do not contribute to dysfunctional HDL in Chinese subjects with coronary artery disease.
Q51245259	N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
Q34230175	Nanopharmaceuticals (part 1): products on the market
Q37780943	National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events
Q47649557	National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey
Q34475442	Near-Normalization of Glucose and Microvascular Diabetes Complications: Data from ACCORD and ADVANCE.
Q28072298	New Era of Lipid-Lowering Drugs
Q53401128	New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
Q61449080	New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease
Q53622322	New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives.
Q90380337	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Q37899907	New approaches to the treatment of nephropathy in diabetes
Q37956122	New horizons for cholesterol ester transfer protein inhibitors
Q37984782	New lipid-lowering drugs: an update
Q26863369	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Q47279052	New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Q44004071	Niacin: the only vitamin that reduces cardiovascular events
Q36820609	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes
Q36329934	No accord for the ACCORD-Lipid trial results
Q37078453	No effect of switching to high-dose rosuvastatin, add-on nicotinic acid, or add-on fenofibrate on serum vitamin D levels in patients with mixed dyslipidemia
Q39383777	Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study
Q37992604	Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?
Q50046562	Non-fasting triglyceride levels in the Korean population with and without ischemic heart disease and cerebrovascular disease.
Q33901914	Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.
Q38074898	Nonalcoholic fatty liver disease: current issues and novel treatment approaches
Q100946503	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Q28084156	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council
Q34423344	Nontraditional serum lipid variables and recurrent stroke risk
Q96129205	Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome
Q38265818	Novel effective drugs for diabetic kidney disease? or not?
Q64262724	Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence
Q38074335	Novel strategies for managing dyslipidemia: treatment beyond statins
Q26823249	Novel therapies focused on the high-density lipoprotein particle
Q39175937	Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance.
Q38186327	Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment
Q30249819	Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.
Q34877739	Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes
Q92339310	Obstacles aux interventions cliniques liées à l’activité physique dans le traitement des maladies cardiométaboliques
Q28076399	Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia
Q38477187	One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response
Q38283386	Ongoing challenges for pharmacotherapy for dyslipidemia
Q24626884	Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk
Q84776096	Optimal blood pressure for a patient with type 2 diabetes mellitus: insight from the ACCORD study
Q53168850	Optimizing lipid-lowering therapy in the prevention of coronary heart disease.
Q26824004	Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Q40629785	Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance
Q33646630	Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial
Q37909519	Overcoming obstacles in risk factor management in type 2 diabetes mellitus
Q37419411	Overview of omega-3 Fatty Acid therapies
Q42858697	PCSK9 Inhibition: Does Lipoprotein Size Matter?
Q89207225	PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
Q55332945	PCSK9 Inhibitors: An Emerging Class of Medications.
Q41822823	PCSK9 as a therapeutic target for cardiovascular disease
Q26784482	PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Q37996437	PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
Q36360452	PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
Q39200940	PPAR-α agonists are still on the rise: an update on clinical and experimental findings
Q92128876	PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Q37790384	PPARs as therapeutic targets in cardiovascular disease
Q39145017	PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.
Q26771753	PPARs: Protectors or Opponents of Myocardial Function?
Q38038289	PPARα as a therapeutic target in inflammation-associated diseases
Q35247278	PURLs: Add a fibrate to a statin?
Q48923906	Paradox of using intensive lowering of blood glucose in diabetics and strategies to overcome it and decrease cardiovascular risks.
Q33776208	Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patients
Q37192024	Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction
Q38757894	Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment
Q35689882	Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey
Q36197709	Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib
Q92892621	Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
Q36366326	Peroxisome Proliferator-Activated Receptor-α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia
Q36261125	Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions
Q37992593	Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes
Q26866784	Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review
Q37025572	Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study
Q38473168	Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study
Q37142852	Personalized vascular medicine: individualizing drug therapy
Q38203774	Pharmacogenomics, lipid disorders, and treatment options
Q34628781	Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk
Q39320400	Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins
Q38072617	Pharmacologic interactions of multidrug therapy for dyslipidemia
Q37973129	Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes
Q39015072	Pharmacological management of diabetic dyslipidemia
Q37842120	Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Q38130111	Pharmacotherapies for lipid modification: beyond the statins
Q37801374	Pharmacotherapy of dyslipidemias in the adult population
Q84764505	Pharmacotherapy: ACCORD Blood Pressure and ACCORD Lipid: how low can we go?
Q84639364	Pharmacotherapy: Implications of high-dose statin link with incident diabetes
Q39908570	Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia
Q37549374	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.
Q37287426	Polyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice.
Q28076119	Post-transplant dyslipidemia: Mechanisms, diagnosis and management
Q38460480	Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies
Q37639159	Postprandial Hyperlipidemia and Remnant Lipoproteins
Q39440767	Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
Q47875819	Practical aspects in the management of statin-associated muscle symptoms (SAMS).
Q38014975	Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia
Q92399114	Prediction of Proliferative Diabetic Retinopathy to Asymptomatic Obstructive Coronary Artery Disease in Chinese Type 2 Diabetes Individuals: An Exploratory Study
Q43718248	Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study
Q37027567	Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy
Q55154739	Prevention and management of statin adverse effects: A practical approach for pharmacists.
Q40087045	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
Q38295069	Primary prevention of atherosclerotic cardiovascular disease: controversies and clinical considerations
Q33972551	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
Q35622601	Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study
Q50870845	Proceedings of the Christiana Care Health System Value Institute Value Symposium.
Q29619982	Progress and challenges in translating the biology of atherosclerosis
Q38839105	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.
Q36138368	Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities
Q37135042	Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia
Q39988795	RAS blockade for every diabetic patient: pro and con.
Q98174765	Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week
Q33833360	Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia
Q33578422	Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial
Q37466366	Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis
Q48131156	Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus
Q34343533	Recent advances in preventing cardiovascular disorders by managing lipid levels
Q37892300	Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus
Q36443768	Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians
Q93609057	References
Q93609219	References
Q38160494	Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes
Q64914760	Relationship between CETP gene polymorphisms with coronary artery disease in Polish population.
Q35088129	Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL.
Q37390626	Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
Q36351005	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease: the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation Study
Q43990488	Repeat measurements of glycated haemoglobin A(1c) and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus
Q36968971	Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges
Q82085286	Residual cardiovascular risk in secondary prevention
Q26996039	Residual macrovascular risk in 2013: what have we learned?
Q30419512	Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants
Q38239205	Revising the high-density lipoprotein targeting strategies - insights from human and preclinical studies
Q38430793	Role for combination therapy in diabetic dyslipidemia
Q38221965	Role of HDL in those with diabetes
Q29994487	Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations
Q38546383	Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy
Q37811855	Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
Q27000731	Role of lipotoxicity in endothelial dysfunction
Q37973966	Role of the PPAR-α agonist fenofibrate in severe pediatric burn
Q93120785	Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease
Q41753267	Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis
Q34481529	Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
Q38541832	Safety considerations with fenofibrate/simvastatin combination.
Q42637141	Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials
Q37854747	Safety review of combination drugs for hyperlipidemia
Q38352759	Saroglitazar for the treatment of dyslipidemia in diabetic patients
Q35492306	Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence
Q37882225	Screening for type 2 diabetes and dysglycemia
Q34237385	Secular trends in treatment and control of type 2 diabetes in an American Indian population: a 30-year longitudinal study
Q38110581	Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists
Q59797390	Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies
Q91875427	Serum lipid management in patients with type 1 and type 2 diabetes: a hospital-based cohort study
Q36469056	Serum lipid profile of newly diagnosed hypertensive patients in nnewi, South-East Nigeria
Q34286013	Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data
Q42931999	Should glucose-sparing prescriptions be expected to reduce the cardiovascular risk of peritoneal dialysis patients?
Q42945058	Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?
Q37346390	Should we start all patients with diabetic retinopathy on fenofibrates?
Q33406100	Simvastatin and amlodipine induced thrombocytopenia in the same patient: double trouble and a literature review
Q89537341	Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
Q37412792	Standards of care for type 2 diabetes in China.
Q34425055	Standards of medical care in diabetes--2011.
Q24632533	Standards of medical care in diabetes--2012
Q29620309	Standards of medical care in diabetes--2013
Q38881156	Statin combination therapy and cardiovascular risk reduction
Q48145497	Statin drug interactions and related adverse reactions: an update
Q37700224	Statin use and all-cause and cancer mortality: BioBank Japan cohort
Q28074144	Statin-Associated Muscle Adverse Events: Update for clinicians
Q28083004	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Q38020453	Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes
Q27010638	Statins in cardiometabolic disease: what makes pitavastatin different?
Q36950782	Strategies for improving cardiovascular health in women with diabetes mellitus: a review of the evidence
Q52599996	Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions.
Q36124203	Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial
Q30454904	Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies
Q38160901	Summarizing the FIELD study: lessons from a 'negative' trial
Q89685776	Supporting care for suboptimally controlled type 2 diabetes mellitus in general practice with a clinical decision support system: a mixed methods pilot cluster randomised trial
Q36602779	Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis
Q36712679	Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series
Q36746311	Systematic review and meta-analysis of 16 randomized clinical trials of radix astragali and its prescriptions for diabetic retinopathy
Q36745091	Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone
Q38904497	Targeting ApoC-III to Reduce Coronary Disease Risk
Q38431166	Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance
Q38553529	Targeting inflammation in metabolic syndrome.
Q24186667	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
Q24202505	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
Q24236456	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
Q41725917	The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence
Q42418260	The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cholesterol management and for cardiovascular risk stratification: a reappraisal
Q36783686	The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses
Q35871965	The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus
Q92333057	The Diagnosis and Treatment of Hypertriglyceridemia
Q30662013	The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)
Q94237982	The Effect of Pharmacy-Led, Small-Group Academic Detailing on Prescribing Patterns in an Ambulatory Care Clinic
Q57475802	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk
Q64923599	The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review.
Q41884591	The Proatherogenic Effect of Chronic Nitric Oxide Synthesis Inhibition in ApoE-Null Mice Is Dependent on the Presence of PPAR α.
Q89534430	The Rise and Fall "ing" of the HDL Hypothesis
Q28550746	The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin
Q34106233	The Role of PPARα Activation in Liver and Muscle
Q52722809	The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator 1α (PGC-1α) in Kidney Disease.
Q36882866	The Treatment of Disorders of Lipid Metabolism
Q36517644	The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females
Q42773416	The causes and consequences of low levels of high density lipoproteins in patients with diabetes
Q38246002	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management
Q35332645	The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia
Q46962775	The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.
Q34615937	The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Q37978209	The emerging role of HDL in glucose metabolism
Q28072835	The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism
Q37947160	The epidemiological concept of residual risk
Q36047244	The evolution of domain arrangements in proteins and interaction networks
Q38072612	The evolution or revolution of statin therapy in primary prevention: where do we go from here?
Q34042836	The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies
Q30393989	The glucose triad and its role in comprehensive glycaemic control: current status, future management
Q37363449	The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome
Q38118163	The need for combination drug therapies in patients with complex dyslipidemia
Q38267131	The new cholesterol treatment guidelines from the American College of Cardiology/American Heart Association, 2013: what clinicians need to know
Q30357715	The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.
Q38273378	The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.
Q35896110	The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study
Q38005926	The relationship between lung inflammation and cardiovascular disease
Q37997004	The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes
Q37425564	The reversal of cardiology practices: interventions that were tried in vain
Q38083006	The role of early LDL lowering to prevent the onset of atherosclerotic disease
Q35060328	The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Athe
Q35060314	The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study p
Q33776214	The role of triglyceride in cardiovascular disease in asian patients with type 2 diabetes--a systematic review.
Q35602424	The role of triglycerides in atherosclerosis
Q92522639	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction
Q61445463	The triglyceride paradox in the mortality of coronary artery disease
Q50193445	The year in cardiology 2017: prevention.
Q35078274	Therapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment
Q42372998	Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration
Q38596398	Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab
Q38209811	Therapeutic approaches to diabetic nephropathy--beyond the RAS.
Q37902643	Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease
Q37981725	Therapeutic strategies to deplete macrophages in atherosclerotic plaques
Q37825945	Therapies for diabetic dyslipidaemia
Q46108030	Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPARα mice
Q37964515	Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes
Q57112903	Towards more specific treatment for diabetic dyslipidemia
Q33585474	Treating diabetic dyslipidemia: What have we learnt from recent clinical trials?
Q38201721	Treating low high-density lipoprotein cholesterol: what is the evidence?
Q49689988	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.
Q33887783	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Q27026114	Treatment of dyslipidemia
Q34499472	Treatment of dyslipidemia in patients with type 2 diabetes
Q37923978	Treatment of lipid disorders in obesity
Q39556962	Treatment targets in the management of dyslipidemias: which targets in whom?
Q34546861	Trends in diabetes medication use and prevalence of geriatric syndromes in older Mexican Americans from 1993/1994 to 2004/2005
Q92649743	Trials in "True" Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk
Q38932760	Triglyceride Treatment in the Age of Cholesterol Reduction
Q40364483	Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
Q37015549	Triglyceride and cardiovascular risk: A critical appraisal
Q89846775	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab
Q36151033	Triglyceride to high-density lipoprotein cholesterol ratio predicts cardiovascular outcomes in prevalent dialysis patients.
Q58550770	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Q34181381	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Q26745946	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Q38240749	Triglycerides and cardiovascular disease
Q91926577	Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes
Q41104057	Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011.
Q37033898	Type 1 Deiodinase Regulates ApoA-I Gene Expression and ApoA-I Synthesis Independent of Thyroid Hormone Signaling
Q34023548	Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
Q37832118	Type 2 diabetes mellitus in 2010: individualizing treatment targets in diabetes care
Q43491912	Update dyslipidemia
Q37980739	Update of the past year: a review from IDSA 2011.
Q26798326	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association
Q27687851	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.
Q33887918	Update on lipids and C-reactive protein in acute and chronic coronary heart disease
Q45359231	Update: clinical lipidology
Q34961885	Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists.
Q36134940	Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
Q90338365	Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
Q34428524	Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials
Q35903762	Use of fibrates in the United States and Canada
Q26765234	Use of fibrates in the metabolic syndrome: A review
Q97682129	Use of non-LDL-C lipid-lowering medications in patients with type 2 diabetes
Q89312828	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options
Q64337067	Utilization and adherence to guideline-recommended lipid-lowering therapy at an academic medical center
Q47263832	Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S.
Q34135420	Varespladib methyl in cardiovascular disease
Q57269550	Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
Q36082525	Visual assessment of the similarity between a patient and trial population: Is This Clinical Trial Applicable to My Patient?
Q39388920	We Know More Than We Can Tell About Diabetes and Vascular Disease: The 2016 Edwin Bierman Award Lecture
Q38931845	What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
Q37812296	What combination therapy with a statin, if any, would you recommend?
Q82085276	What intervention trials don't tell us: the residual risk in primary prevention
Q39528844	What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?
Q38253965	Why do statins reduce cardiovascular disease more than other lipid modulating therapies?
Q37923968	Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?
Q91975849	Xuezhitong capsule, an extract of Allium macrostemon Bunge, exhibits reverse cholesterol transport and accompanies high-density lipoprotein levels to protect against hyperlipidemia in ApoE-/- mice
Q52813315	[Clinical importance of HDL cholesterol].
Q87437305	[Lipid therapy for patients with coronary heart disease and diabetes. Current state and perspectives]
Q85725390	[Lipids: diagnosis and therapy in type 2 diabetes]
Q83436144	[Optimal lipid treatment: possibilities and current limitations]
Q53204305	[PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?].
Q88025019	[Part I. Fibrates in primary and secondary prevention]
Q88025020	[Part II. Combination statin plus fibrate regimens (free and fixed)]
Q83320620	[Progress in hypertension and diabetes in 2010]
Q87174271	[Treatment of lipid disorders]
Q34486059	log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males
Q38559352	α-Lipoic acid as a triglyceride-lowering nutraceutical
Q38283976	ω-3 carboxylic acids for hypertriglyceridemia

P356	DOI	10.1056/NEJMOA1001282
P932	PMC publication ID	2879499
P698	PubMed publication ID	20228404

P50	author	John Buse	Q6224073
		Hertzel C. Gerstein	Q41696958
		David C Goff	Q96109271
		Faramarz Ismail-Beigi	Q98918532
		ACCORD Study Group	Q98918533
		Jeffrey L Probstfield	Q114443555
		Denise G Simons-Morton	Q125329956
		William T Friedewald	Q125330182
P2093	author name string	Henry N Ginsberg
		William C Cushman
		Lawrence A Leiter
		Richard H Grimm
		J Thomas Bigger
		John R Crouse
		Marshall B Elam
		Peter Linz
		Robert P Byington
		Laura C Lovato
P2860	cites work	Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)	Q27860959
		Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease	Q28139910
		Effects of intensive glucose lowering in type 2 diabetes	Q29547736
		A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group	Q29614889
		Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction	Q29618673
		Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines	Q29619614
		Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group	Q29619877
		Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial	Q29622926
		Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial	Q30080004
		Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)	Q33764951
		MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial	Q33966645
		Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).	Q34161324
		Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease	Q34687253
		Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.	Q36864166
		Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study	Q37105236
		Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial	Q42624958
		Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial	Q44459441
		The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up.	Q44812728
		Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus	Q44819058
		Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans	Q45022898
		Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin	Q45201807
		Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group.	Q50897068
		Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.	Q51910741
		Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods	Q58040103
		Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment	Q67720940
		ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins	Q74627919
		Diabetic dyslipidemia	Q80228440
		Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study	Q83862765
P433	issue	17
P407	language of work or name	English	Q1860
P921	main subject	type 2 diabetes	Q3025883
P304	page(s)	1563-1574
P577	publication date	2010-03-14
P1433	published in	The New England Journal of Medicine	Q582728
P1476	title	Effects of combination lipid therapy in type 2 diabetes mellitus
P478	volume	362

Effects of combination lipid therapy in type 2 diabetes mellitus

scientific article

Reverse relations